Amgen's Repatha Shows Promising Results in New Trial

Amgen's (NasdaqGS:AMGN) Repatha has shown promising results in a new Phase 3 trial, reducing the risk of death for high-risk adults without prior heart attack or stroke. The VESALIUS-CV trial data was presented at the European Society of Cardiology Congress 2026.

The study demonstrated that Repatha can benefit patients beyond those with established cardiovascular events. This could have significant implications for future treatment guidelines and prescribing decisions in cardiovascular risk management.

Repatha is part of Amgen's broader shift towards using data and advanced tools to manage healthcare risks, which may be a key driver of growth in the industry. The company highlighted that this data may inform future treatment guidelines and prescribing decisions in cardiovascular risk management.

The success of Repatha could also have a positive impact on other late-stage cardiovascular drugs facing pricing pressure and biosimilar competition.